Premium
Declining levels of CXCL10 over time as a marker for arthritis development in patients with psoriasis
Publication year - 2020
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.19515
Subject(s) - psoriasis , psoriatic arthritis , medicine , arthritis , dermatology , population , environmental health
Psoriasis is a common skin condition that is found in about 2‐3% of the population. About 30% of these individuals also develop a specific form of arthritis called psoriatic arthritis (PsA). CXCL10, a signaling protein in the body, was previously found to drop in psoriasis patients who go on to develop PsA. This study, based in Canada, aimed to test whether this drop in CXCL10 was specific to the patients that advance to PsA and to monitor its levels over multiple visits. This was done by measuring levels of CXCL10 in the blood of psoriasis patients who developed PsA and those who did not develop PsA over the same timeframe, and was analyzed using statistical models. We found that CXCL10 only declined over time in those psoriasis patients who developed PsA. This trend was found before they were diagnosed with PsA and levels continued to drop afterwards. This study supported the use of CXCL10 as a marker (signal) for identifying psoriasis patients at risk for PsA. Linked Article: Abji et al. Br J Dermatol 2020; 183: 920–927.